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Abstract
Introduction: Primary breast lymphoma (PBL) is a rare form of extranodal lymphoma. The most common pathology is diffuse
large B cell lymphoma and most patients are diagnosed at stages 1 and 2. The therapeutic options available so far include surgery,
radiotherapy, and chemotherapy
Case Presentation: The patient was a 54-year old woman with localized primary breast diffuse large B-cell lymphoma (DLBCL). The
patient underwent 6 courses of chemotherapy with an R-CHOP regimen followed by radiotherapy of the breast and regional lymph
nodes with a dose of 40 Gy. In PET scan done three months later, the patient was in complete remission. Around one year later, the
patient experienced relapse in the contralateral breast.
Conclusions: In the pattern of lapse of patients, there is a tendency for extranodal relapse. In some studies it has been speculated
that there is a high probability of relapse in central nervous system (CNS) and some authorities advocate CNS prophylaxis in these
patients. The best outcome would be for patients treated with chemotherapy including rituximab followed by radiation. We re-
viewed some studies regarding treatment modalities and site of relapse.
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1. Introduction
Primary breast lymphoma (PBL) is a rare extranodal
lymphoma (1). It is defined as the presence of lymphoma
in the breast without the involvement of other extramam-
mary regions (2). It is mainly prevalent among women
while being rare among men (3). Considering its higher
prevalence in women, hormonal factors are considered as
probable causes (2).
The average age of patients is 66-67 years. Most pa-
tients are diagnosed at stages 1 and 2 (4). The most com-
mon pathology is diffuse large B cell lymphoma, though
other pathologies such as marginal zone lymphoma, fol-
licular lymphoma, Burkitt lymphoma, anaplastic large cell
lymphoma, peripheral T cell lymphoma, small lympho-
cytic lymphoma, lymphoplasmacytic lymphoma, mantle
cell lymphoma, and Hodgkin lymphoma have also been re-
ported (2). The most common symptom at the time of diag-
nosis is the presence of a painless mass. Other symptoms
include pain, inflammation, lymph node palpation, and
occasionally as an accidental findings in imaging (5). The
therapeutic options available so far include surgery, radio-
therapy, and chemotherapy (3). In this study, we reported
a patient with primary diffuse large B-cell lymphoma (DL-
BCL) breast lymphoma who experienced an isolated re-
lapse in the contralateral breast after treatment.
2. Case Presentation
The patient was a 54-year-old woman with no family
history, presenting with a mass in her right breast as pri-
mary symptom. There were no B symptoms. A hypoactive
nodule with vascularity plus lymphadenopathy in the ipsi-
lateral axilla was found in sonography.
Core needle biopsy of the breast mass was done and DL-
BCL was reported. Cervical, thoracic, and abdominopelvic
CT scan as well as BMB, did not show involvement of other
sites. The patient underwent 6 courses of chemotherapy
with an R-CHOP regimen followed by radiotherapy of the
breast and regional lymph nodes with a dose of 40 Gy. In
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PET scan done three months later, the patient was in com-
plete remission. Around one year later, the patient noted
a mass in the contralateral breast (Figure 1). In the core
biopsy, the pathology was misdiagnosed as mantle cell
lymphoma at first but after review of morphologic study
and IHC staining DLBCL of non-germinal center was con-
firmed. CD19, CD20, BCL2, MUM1, SOX11 markers were posi-
tive in IHC staining and CD10, Cyclind1, BCL6 were negative
(Figure 2). In the PET scan performed, hypermetabolic mul-
tifocal soft tissue density mass in the left breast with SUV
max 14 was reported, while there was no uptake in other
regions. The patient received three courses of chemother-
apy with R-CHOP regimen and the treatment was tolerated
well. There was no sign of disease in the post chemother-
apy CT scan. Radiation therapy including whole breast and
regional lymph nodes with a dose of 40 Gy was done. There
were no serious radiation side effects. In 3-month follow-
up, the patient was disease-free.
3. Discussion
PBL is a rare form of extranodal lymphoma so there
are a limited number of relevant studies (1). In this dis-
ease, there are 2 clinicopathologic scenarios: (i) the uni-
lateral type similar to breast carcinoma being more com-
mon, that can occur at any age; (ii) bilateral and diffuse-
type in pregnant and breastfeeding women, and has a
pathology similar to Burkitt lymphoma (6). Most patho-
logical cases are high-grade and DLBCL (3). In some stud-
ies, ALCL (anaplastic large-cell lymphoma) in women with
breast implant has been reported, which is mostly local-
ized (7). In imaging studies, such as CT scan, mammogra-
phy or sonography, PBL is usually oval or round with cir-
cumscribed margin, thus fibroadenomas, cyst and breast
carcinoma could be considered as radiological differential
diagnosis. Other clinical differential diagnosis include sar-
coma, mammary dysplasia and inflammatory carcinoma.
Other imaging modalities such as PET scan is not specific
and could mimic carcinoma (8).
Definitive diagnosis is based on pathologic features.
Epithelial markers such as cytokeratin are positive in duc-
tal carcinoma and negative in lymphoma. Differentiation
of lymphoma subtypes is possible by IHC and molecular
features such as translocations. Ki67 proliferation rate of
more than 40% demonstrates high-grade lymphoma and
below 10% to 20% illustrates low-grade lymphoma (9).
In the pattern of relapse of patients with primary
breast lymphoma, there is a tendency for extranodal re-
lapse (2). So, we try to exploring the pattern of relapse and
the treatments available for PBL.
In the study by Aviles et al., covering 96 PBL patients,
combination treatments i.e. radiation and chemotherapy
with CHOP regimen, lead to the best outcome compared
to a single modality, with the most relapses occurring in
CNS. Thus, CNS prophylaxis might be considered in these
patients (10).
In the study by Jeanneret-Sozzi et al., investigating 84
PBL patients, pattern of relapse was mostly lymphatic, fol-
lowed by CNS and BM. Other sites of relapse were skin,
lungs, spleen, muscles, orbit, stomach, Waldayer ring, and
liver. The local relapse rate in that study was 12% (3).
In the study by Ryan et al., 204 patients with PBL were
investigated including 5% of cases being bilateral. The pa-
tients received single modality or combination treatment
including 80% chemotherapy with or without surgery or
chemotherapy with radiation in 62% of patients who re-
ceived systemic therapy. The median overall survival (OS)
in these patients was 8 years. The relapse occurred in the ip-
silateral breast during 2.6 years of the primary treatment,
while relapse in the contralateral breast occurred in 13.3
years. In the relapse of unilateral cases, 4% was ipsilat-
eral and 9% was contralateral. Breast radiotherapy lowered
ipsilateral relapse rates. With radiation to the regional
nodes, regional relapses tended to diminish (11).
The multicenter study of Yhim et al. assessed 33 pri-
mary breast DLBCL. Treatment schedule consisted of 6 cy-
cles of R-CHOP and 4 doses of IT-MTX. Local radiation was
not administrated. After the median follow-up of 46.1
months, 2 years progression free survival was 81.3%. Four
patients relapsed in the CNS and 2 patients in the breasts.
This study showed chemotherapy with rituximab and CNS
prophylaxis without routine local radiation may be a suffi-
cient approach (12).
We reviewed some studies including primary breast
DLBCL in regarding primary treatment modalities and the
site of relapses in the Table 1.
The early diagnosis of primary breast DLBCL, and dif-
ferentiating it from other benign and malignant breast tu-
mors, including other types of Hodgkin and non-Hodgkin
lymphoma have an important role in treatment and prog-
nosis, and patients would be spared from unnecessary pro-
cedures such as surgery. As in our case, there is a rare but
possible incidence of metachronous PBL, thus close follow-
up by physical examination and imaging may detect dis-
ease in the early and curable stage.
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Figure 1. Pre chemotherapy CT scan shows an irregular hypodense mass in the left breast
Figure 2. Histologic view shows diffuse infiltration of medium-sized pleomorphic centrocytoid lymphoid cells admixed with a few small lymphocytes and histiocytes.
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Table 1. Review of Initial Treatment and Pattern of Relapse in Primary Breast DLBCL
Study/Year Number of Patients/
Pathology
Primary Treatment Modalities Sites of Relapse
Ryan et al., 2008 (11) 204, DLBCL Chemotherapy, +/- surgery, +/- RT, 8 patients CNS
prophylaxis
32 breast, 13 regional node, 11 CNS, 11 other nodal
site, 28 other extranodal, 2 BM
Yhim et al., 2012 (13) 25, DLBCL 3 - 4 cycles R-CHOP + RT, Or 6 - 8 cycles R-CHOP +/- RT,
2 patients CNS prophylaxis
2 isolated nodal, 5 breast or CNS
Hosein et al., 2014 (14) 76, DLBCL CHOP +/- Rituximab, Or Hyper-CVAD +/- Rituximab,
+/- RT, Or no chemotherapy, 9 patients CNS
prophylaxis
10 breast: 5 ipsilateral, 3 contralateral, 2 bilateral; 12
CNS
Ou et al., 2014 (15) 23, 21;, DLBCL 3 mastectomy, 1 RT, 7 Rituximab, All chemotherapy 2 contralateral breast, 3 CNS, 4 distant nodes
Zhang et al., 2016 (16) 24, DLBCL 1 Surgery, 4 - 6cycles CHOP or chop like, +/-
Rituximab (10), +/-RT (12), 4 CNS prophylaxis
1 BM, 1 breast, 1 skin
Yhim et al., 2020 (12) 33, DLBCL 6 cycles R-CHOP, + CNS 4 CNS, 2 breast: 1 ipsilateral, 1 contralateral
Abbreviations: RT, radiation therapy; CNS, central nervous system; CHOP, cyclophosphamide, adriamycin, vincristine, prednisolone; Hyper-CVAD, cyclophophamide,
vincristine, adriamycine, dexamethasone, cytarabine, methotrexate, leucovorin.
3.1. Conclusions
In PBL, relapse in the contralateral breast is probable
and the patient should be under regular follow-up and visit
after the primary treatment for early diagnosis of the re-
lapse.
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